sub:provenance {
  beldoc: dce:description "Approximately 61,000 statements." ;
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved." ;
    dce:title "BEL Framework Large Corpus Document" ;
    pav:authoredBy sub:_5 ;
    pav:version "20131211" .
  sub:_4 prov:value "Consistent with this theory, the vascular effects of VEGFC in experimental tumours were reduced when the mice were treated with blocking antibodies against Vegfr2 (REF. 75). On the basis of these observations, tumour-vessel formation can be dissected into pathways that preferentially activate angiogenesis (driven by VEGFR2) and pathways that preferentially activate lymphangiogenesis (driven by VEGFR3), although there is evidence that the receptors share overlapping expression patterns56." ;
    prov:wasQuotedFrom pubmed:12154350 .
  sub:_5 rdfs:label "Selventa" .
  sub:assertion prov:hadPrimarySource pubmed:12154350 ;
    prov:wasDerivedFrom beldoc: , sub:_4 .
}